Literature DB >> 12367708

Direct chiral separation of troglitazone stereoisomers using reversed-phase high-performance liquid chromatography.

Nobuyuki Suzuki1, Akira Takemura, Akifumi Miyamoto, Takao Yoshioka, Shinya Tsutsumi, Takao Kawasaki.   

Abstract

A simple HPLC method for the direct chiral separation of troglitazone stereoisomers was developed. The separation was performed on a reversed-phase cellulose-derivertized chiral column (Chiralcel OJ-R) using a mobile phase consisting of methanol-acetic acid (1000:1, v/v) at a flow rate of 0.5 ml/min. The peak areas of stereoisomers separated from 0.13 to 0.75 mg/ml of troglitazone had good linearity, with correlation coefficients > 0.999 in the reversed-phase mode. The repeatability of the ratios of stereoisomers isolated from 0.5 mg/ml of troglitazone had a relative standard deviation of 0.1-0.2%. The relative sensitivities of the four isomers at UV 285 nm were similar, as each response factor was within the range of 0.99-1.01. Troglitazone racemized at the chiral center of the thiazolidine ring in methanol solution, but was found to be stable for 24 h in methanol-acetic acid (1000:1, v/v). This method was applied to the stereoisomeric analysis of troglitazone in pharmaceutical formulations and used to evaluate the constancy of the stereoisomer ratio in the manufacturing process and stability testing. Copyright 2002 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12367708     DOI: 10.1016/s0731-7085(02)00391-6

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  2 in total

1.  Structural basis for activation of fatty acid-binding protein 4.

Authors:  Richard E Gillilan; Stephen D Ayers; Noa Noy
Journal:  J Mol Biol       Date:  2007-08-02       Impact factor: 5.469

2.  13C NMR spectroscopy for the quantitative determination of compound ratios and polymer end groups.

Authors:  Douglas A L Otte; Dorothee E Borchmann; Chin Lin; Marcus Weck; K A Woerpel
Journal:  Org Lett       Date:  2014-03-06       Impact factor: 6.005

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.